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ORIGINAL ARTICLE
Frequency of metabolic syndrome in psychiatric patients, is this the time to
develop a standardized protocol to reduce the morbidity from an acute care
psychiatry unit
Tariq Munshi,1 Archana Patel,2 Mir Nadeem Mazhar,3 Tariq Hassan,4 Emad uddin Siddiqui5

Abstract
Objective: To determine the frequency of Metabolic Syndrome among psychiatric patients and to look for the
correlation between the two medical conditions.
Methods: The cross-sectional study was conducted from February to April 2013 at the acute care psychiatry inpatient unit at Kingston General Hospital, Ontario, Canada, and comprised adult patients of both genders diagnosed
under the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. For Metabolic Syndrome,
definitions outlined by the International Diabetes Federation were used. The patients were divided into two groups
on the basis of presence or absence of the Syndrome and were compared for clinical and demographic
characteristics. SPSS 22 was used for statistical analysis.
Results: Of the 50 patients in the study, 24(48%) were found to have Metabolic Syndrome. Besides, 40(80%) patients
were taking atypical antipsychotics regardless of the diagnosis; 20(83%) among those with the Syndrome, and
20(77%) among those without it.
Conclusions: Patients at high risk of developing metabolic syndrome need to be identified early so that an
individualised care plan can be formulated. Identifying the variables to make a management plan is vital.
Keywords: Metabolic Syndrome, Psychiatry, Canada. (JPMA 65: 54; 2015)

Introduction
The Metabolic Syndrome (MS) is a combination of medical
disorders which increases the risk of developing
cardiovascular disease (CVD), obesity and Diabetes
Mellitus (DM).1,2 It has been estimated that the frequency
of obesity and DM has increased during the last two
decades in the United States which is directly linked to
CVD.1 MS directly increases the risk of developing CVD. An
increased waist circumference (WC) is the central feature
and is associated with high fasting blood glucose (FBG)
and hypertension as well as lipid dysregulation. Central
obesity and insulin resistance are considered high-risk
factors for MS.3,4
MS is very common in the general population. The
prevalence rates have been estimated to be around 25%
throughout the world.5 MS patients are three times more
likely to have a heart attack or stroke compared to people
without MS, and twice likely to die.6 According to data
from the 3rd National Health and Nutrition Examination
Survey (NHANES III 1988-1994), the prevalence of MS in
adult American population is 23.7%.7
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Studies have shown that the prevalence of MS is much
higher among psychiatric patients compared to the
general population. Genetic predisposition to weightgain, lifestyle factors, certain diseases and the effects of
the treatment are considered to be the predisposing
factors.8 In addition to the physical manifestations, MS has
implications regarding predisposition, precipitation and
perpetuation of the illness. The patients describe feelings
of their brain being in a fog, constant tiredness, difficult to
control, anxiety and weight-gain impacting the already
beleaguered self-esteem. The prevalence of MS in people
with Schizophrenia and Schizoaffective Disorder has been
estimated to range from 2.4% to 62%.9-12 In a US study, for
example, more than 30% patients met the criteria for
MS.13 People with severe and persistent mental illness
have a reduced life expectancy. Patients with MS
associated with mental illness generally live 25 years less
than the general population. Cardiovascular
complications are the major cause of death among
people with chronic Schizophrenia.8 Patients with severe
and persistent mental illness such as Schizophrenia and
Bipolar Disorder are more likely to develop cardiovascular
disease,14 which contributes to increased rates of
mortality in this group. A study from Denmark has shown
remarkable reduction of life expectancy of 18.7 years in
men and 16.3 years in women suffering from
Schizophrenia. In patients with Bipolar Disorder, life
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expectancy was 13.6 years in men and 12.1 years
shorter.14 More than two-third deaths among mentally ill
patients were attributed to physical health, CVD (29.9%),
cancers (13.5%) and suicide (13.9%).15 In the United
Kingdom, mortality rate of psychiatric patients with
Schizophrenia rose from 1.6 to 2.2 in 2006, compared to
1999, and for those with Bipolar Disorder it went up from
1.3 in 1999 to 1.9 in 2009.16
The current study was planned to determine the
frequency of MS in individuals admitted to an acute
psychiatric unit as well as to look for the correlation
between mental health problems and MS in this
population.

Patients and Methods
The cross-sectional study was conducted following
approval from the Research Ethics Board at Queen's
University, Ontario, Canada, from February to April 2013 at
the acute care psychiatry in-patient unit at Kingston
General Hospital, Canada.
Adult patients of either gender with acute psychiatric
problems diagnosed under the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-IV) were
enrolled. For MS, definitions outlined by the International
Diabetes Federation (IDF) were used. The study
population comprised patients with acute symptoms or
newly diagnosed psychiatric illnesses. Chronic severe
mental illness can present ranging from chronic severe
mental illness to an adjustment disorder, primary
addiction issues, along with primary triggering factors like
medications, socioeconomic and other situations. Such
cases were excluded and so were those with dementia.
Informed consent from all patients was obtained, and
written material was given to each patient, describing the
purpose of study and the rights of the subjects.
Medical records of the selected patients were reviewed by
the primary physician on a predesigned and pretested
form. The data collection form and procedure was
rechecked randomly by other investigators. Demographic
and clinical data, including age, gender, clinical diagnosis,
antipsychotics, and other psychotropic medications,
treatment of metabolic conditions like blood pressure
(BP), FBG, total cholesterol (TC), triglycerides (TG), highdensity lipoprotein (HDL) and low-density lipoprotein
(LDL) levels. Those who did not have these investigations
done already had morning blood samples drawn after a
period of 12-hour fasting and were tested for FBG and
lipid profile. Each patient underwent measurement to
determine their WC. It was taken at midpoint between
iliac crest and lower rib at the level of umbilicus with the
patient standing.
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For MS, IDF definition2,17 was used which stipulated any 2
of the following: raised TG>150 mg/dl (1.7 mmol/L) or
prescription for lipid abnormality; reduced HDL<40mg/dl
(1.03 mmol/L) in males and <50mg/dl (1.29mmol/L) in
females; raised BP Systolic >130 or Diastolic >95 or on
prescribed drugs; raised FBG>100 mg/dl (5.6mmol/L) or
previously diagnosed Type 2 DM; central obesity >94cm
for Europoid men and >80cm for Europoid women. In the
US, Adult Treatment Panel 3rd Edition (ATP III) values
(102cm males and 88cm females) continue to be used.[18]
South Asian, Chinese and Japanese have 90cm males and
80cm females, while Mediterranean, Sub-Sahara and
Middle East use Europoid criteria and ethnic South and
Central Americans use South Asian criteria.
The participants were divided into those diagnosed with
MS and without MS. The two groups were compared for
all clinical and demographic information using SPSS 22.
Both parametric and non-parametric tests were
conducted. Frequency command was used to determine
rates. Explore command was used to examine data for
normality. For continuous data, t test was conducted,
while Chi Square test was conducted for categorical data
for comparisons.

Results
There were 50 patients with ages ranging from 18 to 72
years and a mean of 42.3±15 years. There were 29(58%)
females and 21(42%) males. Depression was found in
16(32%) patients, followed by Bipolar Disorder 15(30%)
and Schizophrenia 9(18%). Overall, 40(80%) participants
were taking antipsychotics (atypical antipsychotics) and
9(18%)
needed
antipsychotic
poly-pharmacy.
Cardiovascular risk factor (smoking) was present in
25(50%) patients. Of the total, 24(48%) patients had MS,
while 26(52%) were without it. There were no statistically
significant differences in any of the clinical or demographic
characteristics between the two groups (Table).
Among those without MS, 20(79.16%) had hypertension,
14(54.16%) had hypertriglyceridaemia, 18(70.83%) had

Figure-1: Individual abnormalities in patients not meeting the criteria for Metabolic
Syndrome.
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Table: Comparison between those with and without metabolic syndrome, where age is mean (SD) and the rest of the variables are number (%).

Mean age in years
Male n (%)
Female n (%)
Diagnosis n (%)
Schizophrenia
Depression
Bipolar Disorder
Other non psychotic Disorders
Other psychotic disorders
Treatment n (%)
Antipsychotic
Atypical antipsychotic
Polypharmacy
Smoking yes

Metabolic Syndrome (n=24)

No Metabolic Syndrome (n=26)

*

p

44.5±15.4
9 (37.5)
15 (62.5)

40.38±15.3
12 (46.2)
14 (53.8)

0.48

0.348

0.384

0.536

5 (20.8)
5 (20.8)
9 (37.5)
2 (8.3)
3 (12.5)

4 (15.4)
11 (42.3)
6 (23.1)
1 (3.8)
4 (15.4)

0.721
2.645
0.651
0.446
0.086

0.765

20 (83.3)
4 (20.8)
13 (54.2)

20 (76.9)
6 (15.4)
11 (42.3)

0.321
0.384
0.703

0.874
0.402

Analyses were carried out using a Chi square test, except for age, for which a t test was used for comparisons. * Chi square values, except for age, where it is t value.

Figure-2: Age relation with features of Metabolic Syndrome.

diagnosis or use of antipsychotic medication.19 Similar
prevalence was found in a study which examined
patients on clozapine and found 46% MS prevalence.20,21
The study samples represented the group of the patients
with a wide range of psychiatric disorders and there was a
significant increase in MS prevalence. The rates of MS have
been estimated to be between 2.4 to 62.2% in the
population. A closer estimate would be with the US
population in which rates were found to be nearly 30%.
The rates of MS in our study are higher than those
reported in the US. These higher rates than the
neighbouring US population need to be further
investigated.

low HDL and 11(41.66%) had glucose dysregulation
(Figure-1). In MS patients, central obesity was found in
7(31%).

The current study confirms some of the contributory
factors towards the development of MS already described
in literature.21-23 Schizophrenic patients have been found
to be more vulnerable to abnormalities of glucose
regulation and insulin resistance.21,24

The mean age of MS group was 44.5±15.4 years and that
of the other group was 40.38±15.3 years. The difference
was not statistically significant (p=0.348). None of the
differences were statistically different. The difference
between the percentage of males and females with
hyper-triglyceridaemia was the closest to being
significant (p=0.072).

Discussion
There was a high MS prevalence in the study population,
with 48% meeting the criteria according to IDF definition.
This is similar to 55% reported by a recent study carried
out in patients attending a day centre where, it
concluded, chronic enduring mental illness was
associated with high MS prevalence regardless of

The monitoring of MS has not received the place it
deserves in health system despite high prevalence rates in
psychiatric populations and recommendations from the
best practice guidelines.25,26 The top three barriers are
"lack of integration between mental health and primary
care system", "patient's lack of resources", and "mental
health providers not being trained to provide basic
primary care". Experienced providers identified a lack of
integrated care and patient characteristics as important
barriers to metabolic care, and concluded that the primary
care and public health systems are primarily responsible
for metabolic treatment.25,27 The treatment rates of MS are
low in adults with mental illness. In a study in patients with
Schizophrenia (majority of whom were treated with
second-generation antipsychotics), 30% had DM, 64.4%
J Pak Med Assoc
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had hypertension and 88% had abnormal cholesterol
level, and they did not receive any treatment.24

caution is advised while generalising our results.

The issue remains as to who is primarily responsible for
looking after or at least for identifying health needs of
these patients. It is important to improve collaboration
between primary and secondary tiers in the clinical care
of patients. Prevention is the first step as clearly identified
by the IDF.18 It is important to educate people about
healthy lifestyles, including healthy diet, exercise,
smoking and alcohol cessation. There is evidence from
research that cardiovascular exercise can be therapeutic
in approximately 31% cases with MS. The probable
benefit was to reduce TG levels, with 43% showing
improvement; but FBG or insulin resistance of 91% had no
change.28

High-risk patients need to be identified at the outset so
that an individualised care plan can be formulated and
initiated. This would help in enabling patients to
understand that the identified needs in their case do
include focusing on their physical profile as a priority. The
newer atypical antipsychotics do offer a better metabolic
profile and in certain cases can result in improvement of
the overall picture. This, in addition to psycho-education
of the patient with improved access to physical
healthcare, can lead to reduced morbidity and mortality.
It would be preferable for mental health services to have
their own metabolic tertiary care service clinic. The
medical care of the patients with mental illness requires
effective collaboration between primary care physicians
and psychiatrists. There should be "shared care" that
focuses on physical health within the context of mental
health. There can be closer collaboration with the general
practitioner and the related services pertaining to such
matters to provide best practice to the patients.

There is a need to establish well-being clinics in mental
health setups. The psychiatrists should consider
measuring all the parameters in this regard, like BP and
WC during patient's visit as a practice early on in their
engagement with them. All patients who are on
atypical antipsychotics need to have baseline
screening performed and then monitoring of their
weight, BP, FBG and lipids. Psycho-education, dietary
advice and suggestions to increase physical activity
can take precedence over change in medication,
especially if there is a risk of relapse in patients who
have been stable on them for an extended length of
time. Psychiatrists should consider stopping or
switching antipsychotics if metabolic problem
develops in a close temporal relationship to start a new
antipsychotic with a more favourable profile for such
issues. If this attempt is unsuccessful, then consultation
and referral to family physicians or internist colleagues
should be made.
The strength of the study is that it recruited a
heterogeneous set of population, attending our acute
care in-patients unit in a catchment area service and
covered a broad range of psychiatric diagnosis instead of
being limited to a particular diagnosis and type of
medication.
The limitations of the study were that it had a relatively
small sample of 50 patients and was a cross-sectional view
of the overall picture. No sample size calculation was done
either. Despite the limitation, our findings are consistent
with several previous studies. Therefore, it does help to
identify patients at the risk of developing MS, which
prompts intervention by treating team. Although we
selected all patients at the local unit who consented and
fulfilled the criteria, but we did not include patients from
other local teams due to limited resources. Therefore,
Vol. 65, No. 1, January 2015

Conclusions
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